D-penicillamine-induced pancreatic islet autoantibody production is independent of the immunogenetic background: A lesson from patients with Wilson's disease

Clinical Immunology and Immunopathology

Volumn 89, Issue 3, 1998, Pages 279-283

  Kauschansky, Arieh ^a   Frydman, Moshe ^a   Assa, Sara ^a   Kwon, Oh Joong ^b   Israel, Shoshana ^b   Lazard, Daniel ^a   Sprecher, Elliot ^a   Bloch, Konstantin ^a   Brautbar, Chaim ^b   Vardi, Pnina ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NONE

Author keywords

D penicillamine; Insulin autoantibodies; Islet cell autoantibodies; Wilson's disease

Indexed keywords

AUTOANTIBODY; INSULIN; PENICILLAMINE;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; FEMALE; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENETICS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; MALE; PANCREAS ISLET CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCHOOL CHILD; WILSON DISEASE;

EID: 0032374076     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1998.4609     Document Type: Article

References (29)

1. Palmer J. P., Asplin C. M., Clemons P. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 222:1983;1337-1339.
2. Wilkin T. J., Nicholson S. Antibodies against human insulin. Br. Med. J. 288:1984;349-352.
3. Hirata Y., Tominaga M., Ito J.-I., Naguchi A. Spontaneous hypoglycemia with insulin autoimmunity in Grave's disease. Ann. Intern. Med. 81:1974;214-218.
4. Folling Y., Norman N. Hyperglycemia, hypoglycemia attacks and production of anti-insulin antibodies without previous known immunization. Diabetes. 21:1972;814-826.
5. Feltkamp T. E. W. Fundamental studies on penicillamine for rheumatoid diseases. Scand. J. Rheumatol. 1979;23.
6. Dawkins R. L., Christiansen F. T., Garlep M. J. Autoantibodies and HLA antigens in ocular, generalized and penicillamine-induced myasthenia gravis. Ann. NY Acad. Sci. 377:1981;372-384.
7. Chalmers A., Thompson D., Stein H. E., Reid G., Patterson A. C. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann. Intern. Med. 97:1982;659-663.
8. Benson E. A., Healy L. A., Barron E. J. Insulin antibodies in patients receiving penicillamine. Am. J. Med. 78:1985;857-860.
9. Vardi P., Brik P., Barzil D., Lorber M., Scharf Y. Frequent induction of insulin autoantibodies byD. J. Rheumatol. 19:1992;1527-1530.
10. Brik R., Tennenbaum G., Blank M., Shoenfeld Y., Barzilay D., Bloch K., Vardi P. D. Clin. Exp. Rheumatol. 13:1995;483-488.
11. Frydman M., Varsano I., Cohen A., Kaushansky A. Oral glucose tolerance test (OGTT) in patients with Wilson's disease. J. Endocr. Invest. 11:1989;75.
12. Bonifacio E., Bingly P. Y., Shattock M. Quantification of islet cell antibodies and prediction of insulin-dependent diabetes. Lancet. 335:1990;147-149.
13. Grubin C. E., Daniels T., Toivola B., Landin-Olson M., Hagopian W. A., Li L., Carlsen A. E., Boel E., Michelsen B., Lernmark A. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia. 37:1994;304-350.
14. Gianani R., Rabin D. U., Verge C. F., Yu L., Babu R., Pietropaolo M., Eisenbarth G. S. ICA512 Autoantibody radioassay. Diabetes. 44:1995;1340-1344.
15. Miller S. A., Dykes D. D., Polesky H. F. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16:1988;1215.
16. Kimura A., Sasazuki T. Eleventh international histocompatibility workshop reference protocol for the HLA DNA-typing technique. HLA. 1991;Oxford Univ. Press, New York. p. 397-419.
17. Deschamps I., Khalil I. The role of DQ alpha-beta heterodimers in genetic susceptibility to insulin-dependent diabetes. Diabetes/Metab. Rev. 9:1993;71-92.
18. Pugliese A., Gianani R., Moromisato R., Awdeh Z. L., Alper C. A., Erlich H. A., Jackson R. A., Eisenbarth G. S. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes. 44:1995;608-613.
19. Dawkins R. L., Ziko P. J., Carrano J., Garlepp M. J., McDonald B. L. Immunobiology ofD. J. Rheumatol. 1981;56-61.
20. Sternlieb I., Bennet B., Scheinberg I. H. D. Ann. Intern. Med. 82:1975;673-676.
21. Bucknal R. C., Dixon A., St. J., Glieb E. N. Myasthenia gravis associated with penicillamine treatment for rheumatoid arthritis. Br. Med. J. 1:1975;600-602.
22. Schrader P. L., Petrus H. A., Dahl D. S. Polymyositis and penicillamine. Arch. Neurol. 27:1972;456-457.
23. Crouzet J., Camus J. P., Leca A. P., Cullier D., Lievre J. A. Lupus induced byD. Ann. Med. Intern. 125:1974;71-79.
24. May V., Aristoff H., Le cog G. Syndromes de Cougerot-Sjogren induit par laD. Rev. Rheum. Mal Osteoartic. 44:1977;497-501.
25. Myers M. A., Rabin D. U., Rowley M. J. Pancreatic islet cell cytoplasmatic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes. 44:1995;1290-1295.
26. Zeigler R., Alper C., Awdeh L. Specific association of HLA-DR4 with increased prevalence and level of insulin autoantibodies in first degree relatives of patients with type I diabetes. Diabetes. 40:1991;709-714.
27. Kretzcchmar L., Henning H., Swen M. J., Brocker E. B. Elastosis perforans serpinginosa, überlegungen zur pathogenese anhand eines typischen falles. Hautarzt. 43:1992;640-644.
28. Nagata N., Hurtenbach U., Gleichmann E. Specific sensitization of Lyt 1 + 2 T cells to spleen cells modified by the drugD. J. Immunol. 136:1986;136-142.
29. Hurtenbach U., Gleichmann H., Nagata N., Gleichmann E. Immunity toD. J. Immunol. 139:1989;411-416.